No Complications in Switching from Recombinate to Advate - a Prospective Surveillance in 22 Children

摘要

Since the beginning of the 1980s, the safety of factor VIII concentrates was constantly improved. Milestones were the introduction of safe plasma derived concentrates and the development of the first recombinant concentrates. An advancement of the recent years was the introduction of a plasma/albumin-free recombinant human factor VIII (Advate; Baxter International Inc.). Since Advate replaces Recombinate (Baxter International Inc.), patients with hemophilia A, previously treated with Recombinate had to be switched to another product. We decided to change those patients to Advate. Although data are spare, a change of product had been discussed in the literature as risk factor for the development of inhibitors against factor VIII. We therefore prospectively monitored the switch in regard to complications or the development of inhibitors.